| Literature DB >> 32398117 |
Raquel Lama1, Patricia Pereiro1,2, Valentina Valenzuela-Muñoz2, Cristian Gallardo-Escárate2, Lluis Tort3, Antonio Figueras1, Beatriz Novoa4.
Abstract
Nodavirus, or nervous necrosis virus (NNV), is the causative agent of viral encephalopathy and retinopathy (VER), a severe disease affecting numerous fish species worldwide. European sea bass, a cultured species of great economic importance, is highly susceptible to the disease. To better understand the response of this organism to NNV, we conducted RNA-Seq analysis of the brain and head kidney from experimentally infected and uninfected sea bass juveniles at 24 and 72 hours post-infection (hpi). Contrary to what was expected, we observed modest modulation of immune-related genes in the brain, the target organ of this virus, and some of these genes were even downregulated. However, genes involved in the stress response showed extremely high modulation. Accordingly, the genes encoding the enzymes implicated in the synthesis of cortisol were almost the only overexpressed genes in the head kidney at 24 hpi. This stress response was attenuated after 72 h in both tissues, and a progressive immune response against the virus was mounted. Moreover, experiments were conducted to determine how stress activation could impact NNV replication. Our results show the complex interplay between viral activity, the stress reaction and the immune response.Entities:
Mesh:
Substances:
Year: 2020 PMID: 32398117 PMCID: PMC7218500 DOI: 10.1186/s13567-020-00784-y
Source DB: PubMed Journal: Vet Res ISSN: 0928-4249 Impact factor: 3.683
Figure 1Effects of NNV intramuscular infection in juvenile A Kaplan–Meier survival of NNV-infected and uninfected fish. B Replication of NNV at 24 and 72 hpi in brain and head kidney samples. The level of viral replication was measured by qPCR amplification of the gene encoding the NNV capsid.
Summary of Illumina sequencing, assembly and annotation.
| Description | Value |
|---|---|
| Raw data | |
| Reads per sample | 28 044 852.60 |
| Average lenght (bp) | 101 |
| Number of samples | 24 |
| De novo assembly | |
| Number of contigs | 347 317 |
| Average length (bp) | 723 |
| N75 (bp) | 453 |
| N50 (bp) | 1088 |
| N25 (bp) | 2851 |
| UniprotKB/swiss-prot blast | |
| Successfully annotated contigs (%) | 10.2 |
Figure 2Differentially expressed genes in the brain and head kidney after NNV challenge. Stacked column charts reflect the number and intensity of the DEGs identified in the brain A and head kidney D at 24 and 72 hpi (FC > |2|; FDR < 0.05). Heat maps representing the log2-transformed TPM expression values of the DEGs at 24 and 72 hpi for the brain B, C and head kidney E, F. Colours represent transcript expression ranging from black (less expressed) to yellow (more expressed).
Figure 3GO biological processes enriched in the brain at 24.A and 72 hpi B and in the head kidney at 24 hpi C. No enriched terms were observed for the head kidney at 72 hpi.
Immune-related genes significantly modulated in the brain after NNV challenge.
| Gene Name | 24 hpi | 72 hpi |
|---|---|---|
| Leukocyte cell-derived chemotaxin 2 (LECT2) | ||
| C-type lectin (TETN) | ||
| T-cell leukemia homeobox protein 3 (TLX3) | ||
| Platelet-derived growth factor receptor (PGFR) | ||
| NK-tumor recognition protein (NKTR) | ||
| Eomesodermin (EOMES) | ||
| Probable ATP-dependent RNA helicase DDX17 (DDX17) | ||
| Ig mu chain C region secreted form (IGHM) | ||
| Stimulator of interferon genes protein (STING) | ||
| NLR family CARD domain containing 3 (NLRC3) | ||
| Pentraxin-4 (PTX4) | ||
| Radical S-adenosyl methionine domain-containing protein 2 (RSAD2) | ||
| Complement component C3 (CO3) | ||
| Complement C1q tumor necrosis factor-related protein 1 (C1QT1) | ||
| B-cell lymphoma/leukemia 11A (BC11A) | ||
| Semaphorin-4C (SEM4C) | ||
| Nitric oxide synthase, brain (NOS1) | ||
| E3 ubiquitin-protein ligase TRIM39 (TRIM39) | ||
| Platelet glycoprotein V (GPV) | ||
| Leukocyte cell-derived chemotaxin 1 (CNMD) |
Top 25 up- and down-regulated DEGs in the brain at 24 and 72 hpi.
| Up | Down | ||
|---|---|---|---|
| Blast2GO UniProt/SwissProt description | FC | Blast2GO UniProt/SwissProt description | FC |
| 24 hpi | |||
| Hydroxytryptamine receptor 3E (5HT3E5) | 51.82 | Prolactin (PRL) | −101144.45 |
| Bile acid-CoA:amino acid N-acyltransferase (BAAT) | 13.07 | Somatolactin (SL) | −13670.06 |
| Actin-related protein 2/3 complex subunit 1A(ARC1A) | 12.76 | Somatotropin (SOMA)–growht hormone (GH) | −2711.84 |
| Collagen alpha-1(X) chain (COAA1) | 10.87 | Gonadotropin subunit beta-2 (GTHB2) | −1896.99 |
| B2 bradykinin receptor (BKRB2) | 7.36 | O-acyltransferase like protein (OACYL) | −377.22 |
| Deoxyribonuclease-1 (DNAS1) | 6.95 | Pro-opiomelanocortin (POMC) | −349.84 |
| Deoxyribonuclease-1 (DNAS1) | 6.48 | Serotransferrin-1 (STF) | −240.04 |
| Alkaline phosphatase, tissue-nonspecific isozyme (PPBT) | 6.20 | Thyrotropin subunit beta (TSHB) | −172.68 |
| Proline-rich basic protein 1 (PROB1) | 4.78 | Gonadotropin alpha chain (GLHA) | −71.08 |
| Probable cysteine–tRNA ligase, mitochondrial (SYCM) | 4.68 | Transmembrane protein 130 (TM130) | −27.42 |
| MAGUK p55 subfamily member 4 (MPP4) | 4.34 | LINE-1 type transposase domain-containing protein 1 (LITD1) | −18.39 |
| Acidic repeat-containing protein (ACRC) | 4.20 | Pituitary-specific positive transcription factor 1 (PIT1) | −16.88 |
| Gag-Pol polyprotein (POL) | 4.14 | Troponin T, fast skeletal muscle isoforms (TNNT3) | −16.50 |
| MICAL-like protein 2 (MILK2) | 4.12 | Transcription factor COE1 (COE1) | −16.04 |
| Leucine-rich repeat and coiled-coil domain-containing protein 1 (LRCC1) | 4.07 | Methylmalonyl-CoA mutase, mitochondrial (MUTA) | −15.94 |
| Tetranectin (TETN) | 3.86 | Gonadotropin subunit beta-1 (GTHB1) | −12.59 |
| ATP-binding cassette sub-family A member 1 (ABCA1) | 3.81 | LINE-1 reverse transcriptase homolog (LIN1) | −10.49 |
| Oxysterol-binding protein-related protein 11 (OSB11) | 3.78 | Pituitary homeobox 3 (PITX3) | −10.15 |
| DNA replication complex GINS protein PSF3 (PSF3) | 3.58 | Myosin regulatory light chain 2, skeletal muscle isoform type 2 (MLRS) | −9.10 |
| Filamin-C (FLNC) | 3.57 | NLR family CARD domain containing 3 (NLRC3) | −8.70 |
| Leukocyte cell-derived chemotaxin-2 (LECT2) | 3.55 | LINE-1 retrotransposable element ORF2 protein (LORF2) | −8.66 |
| Deoxynucleoside triphosphate triphosphohydrolase SAMHD1 (SAMH1) | 3.50 | UPF0577 protein KIAA1324 (K1324) | −8.58 |
| Protein largen (LARGN) | 3.41 | NADH dehydrogenase (NDUFA1) | −7.48 |
| High affinity choline transporter 1 (SC5A7) | 3.37 | Regulator of rDNA transcription protein 15 (RRT15) | −7.20 |
| Cathepsin D (CATD) | 3.36 | Fructose-bisphosphate aldolase A (ALDOA) | −6.90 |
| 72 hpi | |||
| Prolactin (PRL) | 4713.60 | Myosin regulatory light chain 2, skeletal muscle isoform type 2 (MLRS) | −47.94 |
| Somatotropin (SOMA) | 1332.49 | Collagen alpha-1(II) chain (CO2A1) | −34.45 |
| Thyrotropin subunit beta (TSHB) | 27.90 | Transposon Ty3-I Gag-Pol polyprotein (YI31B) | −30.32 |
| Probable cysteine–tRNA ligase, mitochondrial (SYCM) | 25.81 | Fructose-bisphosphate aldolase A (ALDOA) | −19.98 |
| Gonadotropin alpha chain (GLHA) | 19.53 | Troponin T, fast skeletal muscle isoforms (TNNT3) | −18.43 |
| Pentraxin-4 (PTX4) | 13.24 | Sodium channel protein type 4 subunit alpha B (SC4AB) | −14.00 |
| Pro-opiomelanocortin (POMC) | 13.23 | Sarcoplasmic/endoplasmic reticulum calcium ATPase 1 (AT2A1) | −13.68 |
| LINE-1 retrotransposable element ORF2 protein (LORF2) | 10.99 | Creatine kinase M-type (KCRM) | −12.46 |
| Serine protease 48 (PRS48) | 9.97 | Actin, alpha skeletal muscle 2 (ACT2) | −11.73 |
| Probable E3 ubiquitin-protein ligase HERC4 (HERC4) | 8.55 | Keratin, type I cytoskeletal 17 (K1C17) | −11.31 |
| Sacsin (SACS) | 7.07 | Parvalbumin alpha (PRVA) | −10.45 |
| C-X-C motif chemokine 9 (CXCL9) | 7.07 | Collagen alpha-1(II) chain (CO2A1) | −9.10 |
| Radical S-adenosyl methionine domain-containing protein 2 (RSAD2) | 6.63 | Keratin, type I cytoskeletal 13 (K1C13) | −8.06 |
| Sacsin (SACS) | 6.37 | DNA damage-inducible transcript 4-like protein (DDT4L) | −5.60 |
| Receptor-transporting protein 3 (RTP3) | 5.81 | Receptor-type tyrosine-protein phosphatase F (PTPRF) | −5.58 |
| Receptor-type tyrosine-protein phosphatase F (PTPRF) | 5.75 | Metabotropic glutamate receptor 8 (GRM8) | −5.54 |
| Complement C3 (CO3) | 5.66 | Alpha-1B adrenergic receptor (ADA1B) | −5.46 |
| Protein quaking-A (QKIA) | 5.57 | Sodium channel protein type 4 subunit alpha B (SC4AB) | −5.30 |
| Inter-alpha-trypsin inhibitor heavy chain H2 (ITIH2) | 5.03 | Amiloride-sensitive amine oxidase (AOC1) | −5.15 |
| LINE-1 retrotransposable element ORF2 protein (LORF2) | 5.02 | DNA damage-inducible transcript 4-like protein (DDT4L) | −5.03 |
| Dynein heavy chain 8, axonemal (DYH8) | 4.99 | Bifunctional heparan sulfate N-deacetylase/N-sulfotransferase 3 (NDST3) | −5.02 |
| Retrovirus-related Pol polyprotein from transposon 412 (POL4) | 4.73 | Leukocyte cell-derived chemotaxin-2 (LECT2) | −4.89 |
| Inter-alpha-trypsin inhibitor heavy chain H5 (ITIH5) | 4.50 | Leukocyte cell-derived chemotaxin 1 (CNMD) | −4.89 |
| WD repeat-containing protein on Y chromosome (WDY) | 4.43 | Feline leukemia virus subgroup C receptor-related protein 2 (FLVC2) | −4.83 |
| Filamin-C (FLNC) | 4.37 | Sulfotransferase family cytosolic 2B member 1 (ST2B1) | −4.79 |
Figure 4Venn diagram of the up- and downregulated DEGs identified in the brain at 24 and 72 hpi. Some contigs showed a reversal of their modulation from upregulated to downregulated, or vice versa, between 24 and 72 hpi.
Genes encoding neurotransmitter receptors significantly modulated in the brain after NNV infection.
| Type of neurotransmitter receptor | Receptor or related protein | 24 hpi | 72 hpi |
|---|---|---|---|
| Serotonin receptors | 5-hydroxytryptamine receptor 3E (5HT3E) | ||
| 5-hydroxytryptamine receptor 5A (5HT5A) | |||
| 5-hydroxytryptamine receptor 1F (5HT1F) | |||
| Glutamate receptors | N-methyl- | ||
| N-methyl- | |||
| N-methyl- | |||
| N-methyl- | |||
| N-methyl- | |||
| α-amino-3-hydroxy-5-methyl-4-isoazolepropionic acid (AMPA) AMPA1 (GluR-1) | |||
| α-amino-3-hydroxy-5-methyl-4-isoazolepropionic acid (AMPA) AMPA2 (GluR-2) | |||
| α-amino-3-hydroxy-5-methyl-4-isoazolepropionic acid (AMPA) AMPA3 (GluR-3) | |||
| α-amino-3-hydroxy-5-methyl-4-isoazolepropionic acid (AMPA) AMPA4 (GluR-4) | |||
| 2-carboxy-3-carboxymethyl-4-isopropenylpyrrolidine (kainate) 5 (GluK5) | |||
| Metabotropic glutamate receptor 1 (mGluR1) | |||
| Metabotropic glutamate receptor 4 (mGluR4) | |||
| Metabotropic glutamate receptor 5 (mGluR5) | |||
| Metabotropic glutamate receptor 8 (mGluR8) | |||
| Vesicular glutamate transporter 1 (VGluT1) | |||
| Vesicular glutamate transporter 2.1 (VGL2A) | |||
| AMPA receptor-interacting protein GRIP1 | |||
| Glutamate receptor-interacting protein 2 (GRIP2) | 2.01 &−2.05 | ||
| Kainate-binding protein. Glutamate receptor U1 (GLRK) | |||
| Sodium-dependent glutamate/aspartate transporter 1 (EAA1, GLAST-1) | |||
| GABA receptors | GABA(A) receptor subunit alpha-2 (GBRA2) | ||
| GABA(A) receptor subunit alpha-5 (GBRA5) | |||
| GABA(A) receptor subunit beta-1 (GBRB1) | |||
| GABA(A) receptor subunit beta-3 (GBRB3) | |||
| GABA(A) receptor subunit beta-4 (GBRB4) | |||
| GABA(A) receptor subunit pi (GBRP) | |||
| Acetylcholine receptors | Muscarinic acetylcholine receptor M2 (ACM2) | ||
| Neuronal acetylcholine receptor subunit alpha-3 (ACHA3) | |||
| Neuronal acetylcholine receptor subunit alpha-3 (ACHA3) | |||
| Neuronal acetylcholine receptor subunit alpha-7 (ACHA7) | |||
| Adrenergic receptors | Alpha-1B adrenergic receptor (ADA1B) | ||
| Alpha-2B adrenergic receptor (ADA2B) | |||
| Alpha-2Db adrenergic receptor (AA2DB) |
Figure 5Modulation of DEGs related to calcium transport and homeostasis in the brain at 24 and 72 hpi. Heat maps representing the log2-transformed TPM expression values of the calcium-related contigs at 24 A and 72 hpi B. Colours represent transcript expression ranging from blue (less expressed) to yellow (more expressed). Representation of the modulation of the calcium signalling KEGG pathway components according to the RNA-Seq results at 24 C and 72 hpi D.
Top 25 up- and downregulated DEGs in the head kidney at 24 and 72 hpi.
| Up | Down | ||
|---|---|---|---|
| Blast2GO UniProt/SwissProt description | FC | Blast2GO UniProt/SwissProt description | FC |
| 24 hpi | |||
| Cytochrome P450 11B, mitochondrial (CP11B) | 7007.72 | Transcription cofactor vestigial-like protein 4 (VGLL4) | −88.03 |
| Steroidogenic acute regulatory protein, mitochondrial (STAR) | 1423.20 | Keratin, type I cytoskeletal 13 (K1C13) | −71.73 |
| Cytochrome P450 11B, mitochondrial (CP11B) | 453.32 | NLR family CARD domain-containing protein 3 (NLRC3) | −64.71 |
| Steroid 21-hydroxylase (CP21A) | 349.77 | Keratin, type II cytoskeletal 8 (K2C8) | −60.16 |
| Steroid 21-hydroxylase (CP21A) | 326.02 | Translocase of chloroplast 34 homolog, chloroplastic (TOC34) | −15.80 |
| Steroid 17-alpha-hydroxylase/17,20 lyase (CP17A) | 307.93 | Carbonic anhydrase 1 (CAH1) | −5.18 |
| Steroid 17-alpha-hydroxylase/17,20 lyase (CP17A) | 95.58 | ||
| 3 beta-hydroxysteroid dehydrogenase/Delta 5– > 4-isomerase type 1 (3BHSD) | 61.79 | ||
| Nuclear receptor subfamily 5 group A member 2 (NR5A2) | 43.00 | ||
| Chemokine-like receptor 1 (CML1) | 17.97 | ||
| Cholesterol side-chain cleavage enzyme, mitochondrial (CP11A) | 4.37 | ||
| 72 hpi | |||
| Acidic mammalian chitinase (CHIA) | 32.07 | Contactin-associated protein-like 5 (CNTP5) | −39.47 |
| Transposon Ty3-I Gag-Pol polyprotein (YI31B) | 10.35 | Elongation factor 1-gamma (EF1G) | −32.60 |
| Myosin-binding protein C, fast-type (MYPC2) | 6.51 | Phosphoserine aminotransferase (PSAT) | −6.24 |
| Fructose-bisphosphate aldolase A (ALDOA) | 5.12 | Lanosterol 14-alpha demethylase (CP51A) | −6.08 |
| Neuronal acetylcholine receptor subunit beta-4 (ACHB4) | 2.84 | D-3-phosphoglycerate dehydrogenase (3-PGDH) | −5.03 |
| Glyceraldehyde-3-phosphate dehydrogenase (G3P) | 2.75 | Calreticulin (CALR) | −4.42 |
| Rieske domain-containing protein (RFESD) | 2.08 | Protein FAM111A (F111A) | −4.16 |
| Calreticulin (CALR) | −3.74 | ||
| Mitochondrial glutamate carrier 1 (GHC1) | −3.43 | ||
| Arachidonate 12-lipoxygenase, 12R-type (LX12B) | −3.20 | ||
| Ubiquitin carboxyl-terminal hydrolase isozyme L3 (UCHL3) | −3.06 | ||
| Fibronectin (FINC) | −3.05 | ||
| Argininosuccinate synthase (ASSY) | −3.04 | ||
| Quinone oxidoreductase PIG3 (QORX) | −2.88 | ||
| Calreticulin (CALR) | −2.76 | ||
| Stromal cell-derived factor 2-like protein 1 (SDF2L) | −2.75 | ||
| Endoplasmic reticulum chaperone BiP (BIP) | −2.71 | ||
| Inositol-3-phosphate synthase 1-A (INO1A) | −2.69 | ||
| Protein disulfide-isomerase A6 (PDIA6) | −2.63 | ||
| Spermidine synthase (SPEE) | −2.62 | ||
| Nuclear mitotic apparatus protein 1 (NUMA1) | −2.49 | ||
| Protein disulfide-isomerase A4 (PDIA4) | −2.47 | ||
| Rac GTPase-activating protein 1 (RGAP1) | −2.45 | ||
| L-lactate dehydrogenase A chain (LDHA) | −2.40 | ||
| Histone chaperone asf1b-B (AS1BB) | −2.36 | ||
Figure 6Cortisol effects during NNV infection.A Kaplan–Meier survival curve representing the higher NNV susceptibility of sea bass carrying intraperitoneal slow-release cortisol implants compared to those inoculated with the vehicle alone. B NNV replication in the brain of sea bass carrying the cortisol implants or the vehicle alone (n = 5 individual samples). Viral replication was detected by qPCR amplification of the gene encoding the NNV capsid. C Expression of the ighm gene in NNV-infected or uninfected fish in the absence or presence of cortisol overload. The data are represented as fold change expression level in those animals carrying cortisol implants compared to those inoculated with the vehicle. D Detection of the IgM protein by ELISA in NNV-infected or uninfected fish carrying cortisol implants or the vehicle alone (n = 5 individual samples). The data are represented as fold change of protein abundance in those animals carrying cortisol implants compared to those inoculated with the vehicle. E Expression of the prl gene in NNV-infected or uninfected fish in the absence or presence of cortisol overload. The data are represented as fold change expression level in those animals carrying cortisol implants compared to those inoculated with the vehicle.
Figure 7Effect of NNV on cellular ROS production and the antiviral activity of oxygen radicals. A ROS production by head kidney leukocytes during in vitro infection with NNV. The data are represented as the fold change relative luminescence units (RLUs) in the infected samples compared to those of the uninfected cells at each sampling point. Statistically significant differences between NNV-infected and control cells were represented with #, whereas differences along time for the infected cells were represented with *. B ROS detection in head kidney leukocytes at 1 and 5 dpi after in vivo infection with NNV. The data are represented as the fold change of the RLUs in the infected fish compared to those measured for the uninfected animals. C Replication levels of NNV after treatment with H2O2 measured by qPCR amplification of the gene encoding the NNV capsid. hpt: hours post-treatment.
Figure 8Modulation of the intracellular calcium content by NNV infection and the effect of cytoplasmic calcium availability on ROS production and NNV replication. A Intracellular calcium measurement with the fluorescent probe FLUO-4 AM in SSN-1 cells during infection with NNV. Values are the fold change of the fluorescence value obtained for the infected cells compared to the uninfected ones. B Calcium content measurement with FLUO-4 AM in brain cells isolated from in vivo NNV-infected sea bass and represented as the fold change value compared to the uninfected fish. C ROS production detection in head kidney leukocytes after in vitro pretreatment with the calcium chelators BAPTA-AM and EGTA and with or without NNV infection for 1 h. The data are represented as the fold change compared to untreated and uninfected cells. D Replication of NNV in SSN-1 cells after pretreatment with calcium channel blockers and chelators and infection with NNV for 48 h. Viral replication was detected by qPCR amplification of the gene encoding the NNV capsid.
Figure 9Schematic representation of the predicted alterations of the hypothalamic-pituitary-interrenal (HPI) axis after NNV infection and its associated effects based on the transcriptome data. Green indicates genes upregulated according to the RNA-Seq data; red indicates genes downregulated according to the RNA-Seq data.